ACE Report Cover
Subsidence and retroversion of femoral stem not affected by tobramycin-laden bone cement
Translate this  ACE Report Translate this  ACE Report Translate this  ACE Report
Lingua
Download Download Download
Scaricare
Cite this Report Cite this Report Cite this Report
Citare
Add to Favorites Add to Favorites Add to Favorites Remove from Favorites Remove from Favorites Remove from Favorites
+ Preferiti
Translate this  ACE Report Translate this  ACE Report Translate this  ACE Report
Lingua
Download Download Download
Scaricare
Cite this Report Cite this Report Cite this Report
Citare
Add to Favorites Add to Favorites Add to Favorites Remove from Favorites Remove from Favorites Remove from Favorites
+ Preferiti
ARTHROPLASTY
Subsidence and retroversion of femoral stem not affected by tobramycin-laden bone cement .
Verified
This report has been verified by one or more authors of the original publication.

OrthoEvidence Journal (OE Journal) - ACE Report

OE Journal. 2013;1(12):91 Acta Orthop. 2012 Apr;83(2):115-20. doi: 10.3109/17453674.2011.652885. Epub 2012 Jan 17
Autori che hanno contribuito

E Bohm M Petrak T Gascoyne T Turgeon

28 patients scheduled for total hip arthroplasty were randomized to receive cementing of components with simplex P cement or simplex T cement (which is simplex P cement with 1g tobramycin added by the manufacturer), to determine the effect of the antibiotic on aseptic component loosening. Radiostereometric analysis (RSA) of migration and rotation of the femoral stem component and clinical outcomes of Harris Hip and Western Ontario and McMaster Universities Arthritis Index (WOMAC) scores were examined over 2 years. The results indicated that there were no significant differences between groups at any time and demonstrated that simplex T cement did not adversely affect component loosening and functional outcomes in total hip arthroplasty over 2 years.


Dettagli sul finanziamento della pubblicazione +
Finanziamento:
Industry funded
Sponsor:
Stryker Orthopaedics
Conflicts:
None disclosed

Rischio di pregiudizio

8,5/10

Criteri di segnalazione

17/20

Indice di fragilità

N/A

Was the allocation sequence adequately generated?

Was allocation adequately concealed?

Blinding Treatment Providers: Was knowledge of the allocated interventions adequately prevented?

Blinding Outcome Assessors: Was knowledge of the allocated interventions adequately prevented?

Blinding Patients: Was knowledge of the allocated interventions adequately prevented?

Was loss to follow-up (missing outcome data) infrequent?

Are reports of the study free of suggestion of selective outcome reporting?

Were outcomes objective, patient-important and assessed in a manner to limit bias (ie. duplicate assessors, Independent assessors)?

Was the sample size sufficiently large to assure a balance of prognosis and sufficiently large number of outcome events?

Was investigator expertise/experience with both treatment and control techniques likely the same (ie.were criteria for surgeon participation/expertise provided)?

Sì = 1

Incerto = 0,5

Non rilevante = 0

No = 0

La valutazione dei criteri di segnalazione valuta la trasparenza con cui gli autori riportano le caratteristiche metodologiche e sperimentali dello studio all'interno della pubblicazione. La valutazione è suddivisa in cinque categorie che vengono presentate di seguito.

4/4

Randomization

4/4

Outcome Measurements

3/4

Inclusion / Exclusion

3/4

Therapy Description

3/4

Statistics

Detsky AS, Naylor CD, O'Rourke K, McGeer AJ, L'Abbé KA. J Clin Epidemiol. 1992;45:255-65

L'Indice di Fragilità è uno strumento che aiuta l'interpretazione dei risultati significativi, fornendo una misura della forza di un risultato. L'Indice di Fragilità rappresenta il numero di eventi consecutivi che devono essere aggiunti a un risultato dicotomico per rendere il risultato non più significativo. Un numero piccolo rappresenta un risultato più debole, mentre un numero grande rappresenta un risultato più forte.

Perché questo studio era necessario ora?

Since the introduction of antibiotic-laden bone cement, laboratory testing has shown that a 1 gram to 20 gram ratio of antibiotic to bone cement powder has a negligible effect on the mechanical strength and fixation properties of bone cement. However, the appropriateness of the laboratory testing has been questioned, since regulatory standards require testing after 24 hours, which does not necessarily translate into long-term clinical success. Furthermore, no study has directly examined antibiotic additives to bone cement with the risk of aseptic loosening of components, indicating the need for this trial.

Qual era la domanda di ricerca principale?

Does Simplex T bone cement increase the risk of aseptic component loosening when measured after 2 years?

Caratteristiche dello studio +
Population:
28 patients (30 hips) scheduled for primary total hip arthroplasty with Exeter femoral stems coupled with Trident acetabular cups (Stryker Orthopaedics). Direct lateral or posterior surgical approaches were performed. Tantalum markers were injected into greater trochanter, lesser trochanter, and femoral shaft for detection of migration using RSA (n=25 hips completed follow-up)
Intervention:
Simplex T Group: Patients received cementing of components with tobramycin-laden Simplex P bone cement. (n=14)
Comparison:
Simplex P Group: Patients received cementing of components with Simplex P bone cement, with no antibiotic added by the manufacturer. (n=11)
Outcomes:
Primary outcome was stem subsidence measured with RSA. Secondary outcomes were stem rotation/retroversion (assessed with RSA) and functional scores (assessed with Harris Hip Score and Western Ontario and McMaster Universities Arthritis Index (WOMAC))
Methods:
RCT, Triple blind
Time:
Follow-up was conducted at 6 weeks (RSA exclusive), 6 months, 1, and 2 years.
Quali erano i risultati importanti?
  • Mean subsidence after 2 years did not significantly differ between groups, with translation of 0.71mm (SD 0.30) in the control group (Simplex P) and 0.77mm (SD 0.36) in tobramycin-laden group (Simplex T) (Difference 0.06, 95%CI -0.21 to 0.34, p=0.6). Component translation did not significantly differ between groups at the 6 month (p=0.9) or 1 year (p=0.7) follow-up periods, either.
  • The two groups did not significantly differ in mean retroversion of component after 2 years: 0.60 degrees (SD 0.72) for Simplex P group versus 0.84 degrees (0.93) for Simplex T group (Difference -0.24, 95%CI -0.94 to 0.47, p=0.5). Progression of retroversion at 6 months (p=0.6) and 1 year (p=0.6) follow-up were not significantly different between groups.
  • Differences were not significant between groups in functional outcomes of Harris Hip Scores and WOMAC Scores at any point in the study. (all p-values>0.2).
  • Cumulative migrations in the second year indicated substantial distal and moderate posterior migration of the stem, which was similar in both groups.
Che cosa devo ricordare di più?

The addition of tobramycin to Simplex P bone cement had no effect on the subsidence and retroversion of the femoral stem, as well Harris hip and WOMAC functional scores, when compared to bone cement without antibiotic after 2 years.

Come influenzerà l'assistenza ai miei pazienti?

The results of this trial indicated that antibiotic-laden bone cement is a safe method of cementing in total hip arthroplasty as it did not affect the subsidence and retroversion of the femoral stem component after 2 years. However, further studies with longer follow-up and larger sample sizes are necessary to assess the long-term results.

DISCLAIMER

Il contenuto di questa pagina è solo a scopo informativo e non intende sostituire la consulenza, la diagnosi o il trattamento medico professionale. Se ha bisogno di cure mediche, si rivolga sempre al suo medico o al pronto soccorso più vicino. Le opinioni, le convinzioni e i punti di vista espressi dalle persone sui contenuti presenti in questa pagina non riflettono le opinioni, le convinzioni e i punti di vista di OrthoEvidence.

0 di 4 articoli mensili GRATUITI sbloccati
Ha raggiunto il suo limite di 4 visualizzazioni di articoli gratuiti questo mese

Accesso a OrthoEvidence a soli 1,99 dollari a settimana.

Rimanga in contatto con le ultime prove. Può disdire in qualsiasi momento.
  • Valutazioni critiche dei più recenti studi randomizzati controllati ad alto impatto e delle revisioni sistematiche in ortopedia.
  • Accesso ai contenuti del podcast OrthoEvidence, tra cui collaborazioni con il Journal of Bone and Joint Surgery, interviste con chirurghi di fama internazionale e tavole rotonde su notizie e argomenti ortopedici.
  • Abbonamento a The Pulse, una newsletter bisettimanale basata sulle evidenze scientifiche, progettata per aiutarla a prendere decisioni cliniche migliori.
Upgrade
Bentornato!
Ha dimenticato la password?
Inizi la sua prova gratuita oggi stesso!

Il suo account sarà affiliato a
e includerà l'accesso gratuito a OrthoEvidence


O
Ha dimenticato la password?

O
Controlli la sua e-mail

Se esiste un account con l'indirizzo e-mail fornito, le verrà inviata un'e-mail di reimpostazione della password. Se non vede l'e-mail, controlli la cartella spam o posta indesiderata.

Per ulteriore assistenza, contatti il nostro team di supporto.

Effettui il login per abilitare questa funzione

Per accedere a questa funzione, deve essere collegato ad un account OrthoEvidence attivo. Effettui il login o crei un account di prova GRATUITO.

Tradurre il Rapporto ACE

OrthoEvidence utilizza un servizio di traduzione di terze parti per rendere i contenuti accessibili in più lingue. Si prega di notare che, sebbene venga fatto ogni sforzo per garantire l'accuratezza, le traduzioni potrebbero non essere sempre perfette.

Come citare questo documento ACE Report

OrthoEvidence. Subsidence and retroversion of femoral stem not affected by tobramycin-laden bone cement. OE Journal. 2013;1(12):91. Available from: https://myorthoevidence.com/AceReport/Show/subsidence-and-retroversion-of-femoral-stem-not-affected-by-tobramycin-laden-bone-cement

Copiare la citazione
Effettui il login per abilitare questa funzione

Per accedere a questa funzione, deve essere collegato ad un account OrthoEvidence attivo. Effettui il login o crei un account di prova GRATUITO.

Funzionalità per i membri Premium

Per accedere a questa funzione, deve essere collegato ad un account OrthoEvidence Premium.

Condividi questo articolo ACE Report